OncLive: ADCs emerge as exciting addition to ovarian cancer treatment
A class of drugs called antibody-drug coagulates (ADC) are designed with a specific target within the tumors that are not present within normal tissue. This targeted approach helps kill tumor cells while sparing healthy cells.
In late 2022, the FDA approved a new ADC called Mirvetuximab Soravtansine-gynx to treat certain types of ovarian cancer. Caroline Billingsley, MD, University of Cincinnati Cancer Center physician and associate professor in UC's College of Medicine, participated in a Q&A with publication OncLive to discuss the current state and future of ADCs in ovarian cancer treatment.
Billingsley said the FDA approval "gives us an exciting option for patients who have already seen a lot of chemotherapy and [experienced] a lot of toxicity.
"This is a drug that we can offer that [has more] limited toxicity and [exhibits] some efficacy. It’s an exciting time to adopt this drug into our treatment lines,” she continued.
Ongoing studies are researching Mirvetuximab Soravtansine-gynx as both a monotherapy and in combination with other treatments, Billingsley said.
"Given that it has a favorable toxicity profile, it’s an ideal drug to combine with other agents," she said.
Featured photo at top of ovarian cancer tumor in animal model courtesy of National Cancer Institute.
Related Stories
Hoxworth Blood Center, Music Hall invite blood donors to a Symphony of Saving Lives on March 31
March 19, 2026
Hoxworth Blood Center, University of Cincinnati, is calling on the music community to roll up their sleeves this March at an unforgettable specialty blood drive at Music Hall, where the power of music meets the power of saving lives.
Pediatric visits can encourage parents to quit smoking
March 18, 2026
Medscape turns to UC human services Professor Ashley Merianos for expert opinion about using pediatric visits to encourage parents to quit smoking.
UC summer program gives high school students hands-on research experience
March 18, 2026
The University of Cincinnati College of Medicine is expanding its Medical Sciences Summer Institute (MSSI) this year with a new medical informatics track.